Annual report [Section 13 and 15(d), not S-K Item 405]

Subsequent Events (Details)

v3.25.1
Subsequent Events (Details) - USD ($)
 12 Months Ended
Mar. 24, 2025
Feb. 27, 2025
Feb. 25, 2025
Dec. 31, 2024
Dec. 31, 2023
Mar. 15, 2024
Dec. 18, 2018
Subsequent Events [Line Items]              
Exercise price per share (in Dollars per share)       $ 0.01      
Gross proceeds (in Dollars)       $ 7,485,000    
Gross proceeds from warrant exercis (in Dollars)       6,000    
Payment for Cash (in Dollars) $ 219            
Subsequent Event [Member]              
Subsequent Events [Line Items]              
Warrants to purchase shares     6,955,528        
Gross proceeds from warrant exercis (in Dollars)     $ 6,500,000        
Consideration amount (in Dollars)   $ 12,000,000          
Subsequent Event [Member] | Registered Pre-Funded Warrants [Member]              
Subsequent Events [Line Items]              
Warrants to purchase shares     805,231        
Subsequent Event [Member] | Private Pre-Funded Warrants [Member]              
Subsequent Events [Line Items]              
Warrants to purchase shares     2,305,869        
Exercise price per share (in Dollars per share)     $ 0.93        
Subsequent Event [Member] | Private Warrants [Member]              
Subsequent Events [Line Items]              
Warrants to purchase shares     5,939,383        
Subsequent Event [Member] | Existing Warrants [Member]              
Subsequent Events [Line Items]              
Exercise price per share (in Dollars per share)     $ 2.311        
Reduced exercise price per share (in Dollars per share)     $ 0.93        
Subsequent Event [Member] | New Warrants [Member]              
Subsequent Events [Line Items]              
Warrants to purchase shares     6,955,528        
Exercise price per share (in Dollars per share)     $ 0.93        
Common Stock [Member]              
Subsequent Events [Line Items]              
Shares of common stock [1],[2]         20    
Warrants to purchase shares           216,650  
Gross proceeds (in Dollars)       $ 19,000      
Common Stock [Member] | Private Warrants [Member]              
Subsequent Events [Line Items]              
Exercise price per share (in Dollars per share) [3]            
Common Stock [Member] | Subsequent Event [Member]              
Subsequent Events [Line Items]              
Shares of common stock     2,828,283        
Private Placement [Member]              
Subsequent Events [Line Items]              
Warrants to purchase shares             2,900,000
Private Placement [Member] | Subsequent Event [Member]              
Subsequent Events [Line Items]              
Gross proceeds (in Dollars)     $ 5,500,000        
[1] See note 12A.
[2] See note 7A.
[3] In November 2017, BiomX Israel issued 298 warrants to its founders. The warrants were fully vested at their grant date and will expire immediately prior to a consummation of an M&A transaction. The warrants did not expire as a result of the Recapitalization Transaction and have no exercise price. The Merger Agreement as described in note 1D does not apply for such M&A transaction as defined in the grant agreement.